Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary:
Foretinib (GSK1363089) is an ATP-competitive inhibitor that targets multiple receptor tyrosine kinases, including VEGFRs and HGF/Met, with nanomolar potency in both biochemical and cellular assays (Schwartz 2022, DOI). It inhibits tumor cell growth, motility, and invasion in models such as B16F10 melanoma and PC-3 prostate cancer cells (APExBIO product data). In vivo, oral dosing at 30 mg/kg reduces metastatic nodules and tumor burden in xenograft models (Schwartz 2022). Foretinib is insoluble in water/ethanol but highly soluble in DMSO, making proper handling critical for reproducible results. This article details its rationale, mechanism, benchmarks, and workflow parameters for translational cancer research.

Biological Rationale

Receptor tyrosine kinases (RTKs) drive oncogenic signaling pathways that regulate tumor growth, angiogenesis, and metastasis. Dysregulation of VEGFR and HGF/Met pathways is observed in multiple solid tumors, including lung, colon, and ovarian cancers. Inhibiting these RTKs can suppress downstream signaling events essential for cancer cell proliferation and migration. Foretinib (GSK1363089) was developed as a broad-spectrum RTK inhibitor to address tumor heterogeneity and bypass resistance mechanisms that emerge with single-target agents (See: Mechanistic Insights, GSK1363089.com). This article extends previous mechanistic analyses by providing experimental benchmarks and integration guidance for modern research workflows.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib (GSK1363089) competitively binds to the ATP-binding pocket of target kinases, preventing phosphorylation and activation of downstream signaling. The primary targets include:

• HGF/Met (hepatocyte growth factor receptor): IC₅₀ = 0.4–9.6 nmol/L (biochemical); ~21–23 nmol/L (cellular MET inhibition)
• VEGFR2/KDR, VEGFR1/Flt-1, VEGFR3/Flt-4: IC₅₀ within the nanomolar range
• Ron, KIT, Flt-3, PDGFR-α/β, Tie-2: potent inhibition at low nanomolar concentrations

Inhibition of Met and VEGFRs disrupts tumor angiogenesis and cell motility. Foretinib blocks HGF-induced scattering and migration, leading to G2/M cell cycle arrest and reduced proliferation in various cancer cell lines (Schwartz 2022, Fig. 3.2). This multikinase strategy counters compensatory signaling that often limits the efficacy of selective inhibitors.

Evidence & Benchmarks

• Foretinib displays IC₅₀ values of 0.4–9.6 nmol/L for target kinases in biochemical assays (APExBIO, product page).
• In cellular assays, MET pathway inhibition occurs at ~21–23 nmol/L, as measured by phospho-Met ELISA (Schwartz 2022, DOI).
• Foretinib suppresses proliferation of B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cells in vitro (Schwartz 2022, DOI).
• Oral administration at 30 mg/kg reduces metastatic nodules and tumor weight in mouse ovarian cancer xenograft models (APExBIO, product page).
• Solubility is ≥31.65 mg/mL in DMSO at room temperature; insoluble in water or ethanol (APExBIO, product page).
• Induces G2/M cell cycle arrest and inhibits HGF-induced migration in functional cell motility assays (Schwartz 2022, DOI).

For additional protocol-focused guidance, see Optimizing Cancer Assays with Foretinib, which emphasizes operational parameters; this article adds detailed mechanistic and benchmark data.

Applications, Limits & Misconceptions

Foretinib is validated for in vitro assays assessing cell viability, proliferation, and motility in diverse cancer cell lines. It is also used in vivo in xenograft models to evaluate anti-metastatic activity. Its multikinase selectivity makes it suitable for studying pathway cross-talk and resistance mechanisms. However, Foretinib is strictly for research purposes and not approved for clinical or diagnostic use.

Common Pitfalls or Misconceptions

• Foretinib is not soluble in water or ethanol; improper vehicle selection reduces assay validity.
• Cellular potency (IC₅₀ ~21–23 nmol/L for MET) is higher than biochemical potency (0.4–9.6 nmol/L); direct comparison may mislead interpretation.
• Short-term stability in solution: Stock solutions must be stored at -20°C and used promptly to prevent degradation.
• Not for human or veterinary therapeutic use; research-only designation is mandatory.
• Multikinase activity may complicate data interpretation in signaling studies without proper controls.

For discussion on precise kinase selectivity and comparison to other inhibitors, see Multikinase Inhibitor for Cancer Research; this article provides updated IC₅₀ data and in vivo efficacy outcomes.

Workflow Integration & Parameters

Foretinib (GSK1363089) (SKU A2974, by APExBIO) should be prepared in DMSO at concentrations up to 31.65 mg/mL. Working dilutions must maintain DMSO below cytotoxic thresholds (typically <0.1–0.5% v/v in cell culture). Store stock aliquots at -20°C and avoid repeated freeze-thaw cycles. For in vitro assays, dose ranges of 10–100 nM are recommended based on cellular MET inhibition benchmarks. In vivo, oral dosing of 30 mg/kg is effective in mouse xenograft models. Controls should include vehicle and pathway-specific inhibitors to dissect multikinase effects. For further troubleshooting and protocol adaptation, see Advance Protocols for Foretinib, which this article extends by integrating new experimental benchmarks.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated multikinase inhibitor for research on tumor cell proliferation, migration, and metastasis. Its nanomolar potency and broad selectivity profile support applications in both in vitro and in vivo models. Proper handling and workflow integration are essential for reproducibility. As research advances, Foretinib will remain a reference tool for dissecting VEGF and HGF/Met signaling in cancer biology. For product specifications and ordering, refer to the APExBIO Foretinib (GSK1363089) page.